<?xml version="1.0" encoding="UTF-8"?>
<p>Some antivirals are being examined in the treatment of COVID-19. However, the results are not sound. Data in terms of efficacy of lopinavir-ritonavir were promising at first, but a recent randomized trial failed to show benefits, especially in later stages of the disease (
 <xref rid="B5" ref-type="bibr">5</xref>). Hydroxychloroquine is another available choice that has been included in many national protocols (
 <xref rid="B6" ref-type="bibr">6</xref>). However, practitioners have been advised to restrict the administration of this drug for clinical trials due to its questionable efficacy and risk of adverse effects (
 <xref rid="B7" ref-type="bibr">7</xref>). The race is still on to find an effective treatment for COVID-19. Most of our experience came from other coronavirus epidemics, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) (
 <xref rid="B8" ref-type="bibr">8</xref>).
</p>
